Spots Global Cancer Trial Database for PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC

Official Title: PINCH - PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC

Study ID: NCT03829007

Conditions

Head and Neck Cancer

Interventions

PD-L1 imaging

Durvalumab

Study Description

Brief Summary: Non-invasive imaging of tumor PD-L1 expression with 89Zr-labeled durvalumab PET/CT predicts response to durvalumab.

Detailed Description: The programmed death 1 (PD1)/ programmed death ligand 1 (PD-L1) pathway plays an important role in regulating the T-cell anti tumor response. Blocking this interaction with the anti PD-L1 monoclonal antibody durvalumab has proven to be effective resulting in durable disease control rates. Currently, PD-L1 expression as determined by immune histochemistry (IH) is the best available biomarker for treatment response, but standardized scoring criteria are lacking and the risk for sampling errors exists. Molecular imaging using 89Zr-labeled antibodies may overcome these limitations, enabling the visualization of PD-L1 expression in primary and metastatic tumor lesions and providing information on the in vivo accessibility of the PD-L1 target following intravenous administration. Besides, a baseline FDG-PET scan will be performed.